Jean Martin Beaulieu

Dr. Jean Martin Beaulieu


Research Focus & Metrics

Academic Career Length

31Years (1996-Present)

(Calculated once Scilit publication data is synced: current year − year of first publication + 1)

Representative Publications

View All Publications
1 March 2011 in Pharmacological Reviews
Verified
Journal Article
Closed access
PDF file
Jean Martin BeaulieuJean Martin Beaulieu
Jean Martin Beaulieu
Raul R GainetdinovRaul R Gainetdinov
Raul R Gainetdinov
G protein-coupled dopamine receptors (D1, D2, D3, D4, and D5) mediate all of the physiological functions of the catecholaminergic neurotransmitter dopamine, ranging from voluntary movement and reward to hormonal regulation and hypertension. Pharmacological agents targeting dopaminergic neurotransmission have been clinically used in the management of several neurological and psychiatric disorders, including Parkinson's disease, schizophrenia, bipolar disorder, Huntington's disease, attention deficit hyperactivity disorder (ADHD1), and Tourette's syndrome. Numerous advances have occurred in understanding the general structural, biochemical, and functional properties of dopamine receptors that have led to the development of multiple pharmacologically active compounds that directly target dopamine receptors, such as antiparkinson drugs and antipsychotics. Recent progress in understanding the complex biology of dopamine receptor-related signal transduction mechanisms has revealed that, in addition to their primary action on cAMP-mediated signaling, dopamine receptors can act through diverse signaling mechanisms that involve alternative G protein coupling or through G protein-independent mechanisms via interactions with ion channels or proteins that are characteristically implicated in receptor desensitization, such as β-arrestins. One of the future directions in managing dopamine-related pathologic conditions may involve a transition from the approaches that directly affect receptor function to a precise targeting of postreceptor intracellular signaling modalities either directly or through ligand-biased signaling pharmacology. In this comprehensive review, we discuss dopamine receptor classification, their basic structural and genetic organization, their distribution and functions in the brain and the periphery, and their regulation and signal transduction mechanisms. In addition, we discuss the abnormalities of dopamine receptor expression, function, and signaling that are documented in human disorders and the current pharmacology and emerging trends in the development of novel therapeutic agents that act at dopamine receptors and/or on related signaling events.

1 July 2005 in Cell
Verified
Journal Article
Closed access
Jean Martin BeaulieuJean Martin Beaulieu
Jean Martin Beaulieu
TSTatyana D. Sotnikova
Tatyana D. Sotnikova
SMSébastien Marion
Sébastien Marion
RLRobert J. Lefkowitz
Robert J. Lefkowitz
Raul R GainetdinovRaul R Gainetdinov
Raul R Gainetdinov
MCMarc G. Caron
Marc G. Caron

24 March 2004 in Proceedings of the National Academy of Sciences
Verified
Journal Article
Closed access
Jean Martin BeaulieuJean Martin Beaulieu
Jean Martin Beaulieu
TSTatyana D. Sotnikova
Tatyana D. Sotnikova
WYWei-Dong Yao
Wei-Dong Yao
LKLisa Kockeritz
Lisa Kockeritz
JWJames R. Woodgett
James R. Woodgett
MCMarc G. Caron
Marc G. Caron
Dopamine (DA) is a neurotransmitter involved in the control of locomotion, emotion, cognition, and reward. Administration of lithium salts is known to inhibit DA-associated behaviors in experimental animal models through unknown mechanisms. Here, we used a pharmacogenetic approach to show that DA can exert its behavioral effects by acting on a lithium-sensitive signaling cascade involving Akt/PKB and glycogen synthase kinase 3 (GSK-3). In the mouse striatum, increased DA neurotransmission arising either from administration of amphetamine or from the lack of the DA transporter results in inactivation of Akt and concomitant activation of GSK-3α and GSK-3β. These biochemical changes are not affected by activation of the cAMP pathway but are effectively reversed either by inhibition of DA synthesis, D2 receptor blockade, or administration of lithium salts. Furthermore, pharmacological or genetic inhibition of GSK-3 significantly reduces DA-dependent locomotor behaviors. These data support the involvement of GSK-3 as an important mediator of DA and lithium action in vivo and suggest that modulation of the Akt/GSK-3 pathway might be relevant to DA-related disorders, such as attention deficit hyperactivity disorder and schizophrenia.

9 July 2004 in Science
Verified
Journal Article
Closed access
PDF file
XZXiaodong Zhang
Xiaodong Zhang
Jean Martin BeaulieuJean Martin Beaulieu
Jean Martin Beaulieu
TSTatyana D. Sotnikova
Tatyana D. Sotnikova
Raul R GainetdinovRaul R Gainetdinov
Raul R Gainetdinov
MCMarc G. Caron
Marc G. Caron
Dysregulation of brain serotonin contributes to many psychiatric disorders. Tryptophan hydroxylase-2 (Tph2), rather than Tph1, is preferentially expressed in the brain. We report a functional (C1473G) single-nucleotide polymorphism in mouse Tph2 that results in the substitution of Pro 447 with Arg 447 and leads to decreased serotonin levels in PC12 cells. Moreover, in BALB/cJ and DBA/2 mice that are homozygous for the 1473G allele, brain serotonin tissue content and synthesis are reduced in comparison to C57Bl/6 and 129X1/SvJ mice that are homozygous for the 1473C allele. Our data provide direct evidence for a fundamental role of Tph2 in brain serotonin synthesis.

24 November 2014 in British Journal of Pharmacology
Verified
Journal Article
Closed access
PDF file
Jean Martin BeaulieuJean Martin Beaulieu
Jean Martin Beaulieu
SEStefano Espinoza
Stefano Espinoza
Raul R GainetdinovRaul R Gainetdinov
Raul R Gainetdinov

1 February 2009 in Annual Review of Pharmacology and Toxicology
Verified
Journal Article
Closed access
Jean Martin BeaulieuJean Martin Beaulieu
Jean Martin Beaulieu
Raul R GainetdinovRaul R Gainetdinov
Raul R Gainetdinov
MCMarc G. Caron
Marc G. Caron
Psychotropic drugs acting on monoamine neurotransmission are major pharmacological treatments for neuropsychiatric conditions such as schizophrenia, depression, bipolar disorder, Tourette syndrome, ADHD, and Alzheimer disease. Independent lines of research involving biochemical and behavioral approaches in normal and/or genetically modified mice provide converging evidence for an involvement of the signaling molecules Akt and glycogen synthase kinase-3 (GSK3) in the regulation of behavior by dopamine and serotonin (5-HT). These signaling molecules have also received attention for their role in the actions of psychoactive drugs such as antidepressants, antipsychotics, lithium, and other mood stabilizers. Furthermore, investigations of the mechanism by which D2 dopamine receptors regulate Akt/GSK3 signaling strongly support the physiological relevance of a new modality of G protein–coupled receptor (GPCR) signaling involving the multifunctional scaffolding protein beta-arrestin 2. Elucidation of the contribution of multiple signaling pathways to the action of psychotropic drugs may provide a better biological understanding of psychiatric disorders and lead to more efficient therapeutics.